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Introduction
Sickle cell anemia (SCA) is associated with unpredictable recurrent acute vaso-occlusive (VOC) pain episodes ("crises") and chronic pain, which can begin early and continue to increase, leading to poor quality of life and shortened survival. 1, 2 Opioid treatment is widely used to treat pain in SCA, but remains a suboptimal approach due to side effects including somatic and psychiatric co-morbidities, dependence liability, and opioid hyperalgesia. [3] [4] [5] Relatively higher doses of morphine are required to treat sickle pain as compared to other conditions, which may increase the risk of side effects. Morphine is also known to increase inflammation via the activation of toll-like receptor 4 (TLR4). 6 We found that TLR4 expression is increased in mast cells and morphine stimulated the release of substance P (SP) from mast cells and promoted SP-and capsaicin-induced neurogenic inflammation in sickle mice. 7 Therefore, while used for treating pain in SCA, morphine may exacerbate existing mast cell activation, neurogenic inflammation and pain.
Morphine and its congeners exert their anti-nociceptive effect via the mu opioid receptor (MOP/R). In addition to MOP/R, the opioid receptor family includes the nociceptin opioid receptor (NOP/R) which is involved in nociceptive signaling via its endogenous peptide ligand nociceptin/orphanin FQ (N/OFQ). 8 NOP/Rs are found in the dorsal root ganglion (DRG), spinal cord and supraspinal regions of the brain involved in nociception. [9] [10] [11] Agonists and antagonists of NOP/R have been demonstrated to influence pain at the peripheral, spinal and supraspinal level in rodent models of neuropathic and inflammatory pain.
12-14
The antinociceptive role of spinal NOP/Rs is suggested to result from an inhibitory action on SPmediated nociception via second-order neurons. 15 SP levels are increased in the serum of patients with SCA and in sickle mice compared to healthy subjects and control mice, respectively. 16, 17 The endogenous NOP/R peptide agonist N/OFQ has been shown to inhibit the release of SP and calcitonin gene-related peptide (CGRP) from sensory nerve endings. 18 Chemically-induced release of neuropeptides from mast cells and capsaicin-sensitive afferent nerve terminals were also attenuated by N/OFQ. 19 Mast cells are tissue-resident inflammatory cells, which can release pro-inflammatory cytokines, neuropeptides and proteases such as tryptase, upon degranulation/activation. 20, 21 Tryptase released from mast cells activates protease activated receptor-2 (PAR-2) on peripheral nerve terminals stimulating the release of neuropeptides and pain. 22, 23 Neuropeptide SP, in turn activates mast cells leading to a vicious cycle of mast cell and neural activation resulting in chronic pain. We found that sickle mice,
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show mast cell activation and mast cell-dependent neurogenic inflammation and pain. 7 Since, NOP/R agonists appear to block neuropeptide release from peripheral nerve endings and mast cells, we examined the possibility of using small-molecule NOP/R agonist AT-200 to treat pain in SCA.
We used transgenic homozygous HbSS-BERK mice, expressing sickle hemoglobin, which show characteristic features of experimental pain observed in human SCA. 16, 24, 25 We demonstrate the antinociceptive activity of a small-molecule NOP/R agonist AT-200 (formerly SR14150) 26 , and the mechanism of its action in sickle mice. 
Methods
Mice
Hypoxia/reoxygenation (H/R)
Mice were exposed to hypoxia with 8% O 2 and 92% N 2 for 3 hours followed by re-oxygenation at room air for 1 h, as previously described by us.
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Detailed descriptions of the following methods are in the Supplementary file.
Somatosensory testing for pain behaviors
Following behavioral measures were performed in a quiet, temperature-controlled room.
16,25
Mechanical paw withdrawal threshold and frequency.
Grip force to determine deep tissue/musculoskeletal pain.
Withdrawal responses to heat stimuli.
7
Withdrawal responses to cold stimuli.
Balance and motor coordination.
Cutaneous Blood Flow
Cutaneous Mast Cell Staining
Laser scanning confocal microscopy (LSCM) of skin
Statistical Analysis
Inferential test in Figure 1 A two-way ANOVA is used in Figure 5 to determine the effect of genotype and/or treatment followed by an unpaired 't' test within treatment category or within genotype. Bonferroni correction was used to adjust for multiple pairwise comparison in all the analyses. P < 0.05 was considered significant. Data were analyzed using Prism 5 software (GraphPad, San Diego, CA).
Results
AT-200 ameliorates hyperalgesia in sickle mice
Mechanical, deep tissue and thermal hyperalgesia increases with age in sickle mice 16 ,25 similar to chronic pain in sickle patients. 1, 16, 25, 32 Therefore, older mice (~18.5 mo) showing increased sensitivity to different stimuli compared to young mice (~4.4 mo) were used to examine the effectiveness of AT-200 ( Figure S1 ). The two-way repeated measures ANOVA shows no significance for comparison with control, whereas different doses of AT-200 in sickle mice show significant interaction over time for all behavioral measures (Table 1) .
Overall, AT-200 at a dose of 10 mg/kg reduced sensitivity to all stimuli in sickle mice to levels = 6.8, p < 0.0001; PWF, grip force and PWL (heat), respectively). Naloxone alone had no effect compared to baseline.
AT-200 inhibits cutaneous mast cell degranulation
Mast cell density/mm1 1
(green), CD117 (red), and tryptase (turquoise) in the skin of sickle mice, which was reduced appreciably upon AT-200 treatment ( Figure S2 ).
AT-200 inhibits neuropeptides and inflammatory cytokines.
Plasma of sickle mice showed a nearly 1.4-fold and a 1. Acute pain due to VOC can be recurrent, lasting several days and requiring hospitalization. Cromolyn sodium for 5 days reduced, plasma CGRP and SP, inflammation marker SAP, and markers of mast cell activation, viz. tryptase and β-hexosaminidase. 7 Release of inflammatory cytokines TNF-α, IL6 and RANTES from the skin of sickle mice was also significantly reduced upon treatment with mast cell inhibitors, suggesting that activated mast cells contribute to inflammation in SCA. 7 Mast cell activation has also been strongly implicated in the development of pain. on peripheral mast cell activity observed herein is consistent with dose-dependent inhibition of mucosal mast cell density for up to 52-hours upon s.c. infusion of N/OFQ into the distal colon. 46 Increased SP and CGRP in sickle mouse skin and plasma are accompanied by neurogenic inflammation and TRPV1 activation in the peripheral nerve terminals. 7, 28 N/OFQ reduces local axon reflex-mediated neurogenic inflammation by reducing the release of vasoactive neuropeptides CGRP and SP from sensory afferent nerve terminals in the periphery. 18 In the chronically denervated rat model, an intraperitoneal injection of N/OFQ inhibited the release of neuropeptides SP, CGRP and somatostatin from isolated rat trachea in response to capsaicin or bradykinin. 19 The concomitant decrease in mast cell degranulation and serum SP, SAP and cytokines in sickle mice following AT-200 treatment is suggestive of reduced nociceptor excitation and decreased inflammation. Since SP is elevated in SCA patients ranging from 2-18 years of age compared to age-matched normal subjects, 17 2 0 
Material and Methods
Somatosensory testing for pain behaviors
Behavioral measures were performed in a quiet, temperature-controlled room dedicated to behavioral testing of mice, as previously described. 47,48 All mice were acclimated to the room and to the tests before collecting data.
Mechanical paw withdrawal threshold and frequency. Mechanical allodynia was measured as paw withdrawal threshold using Von Frey filaments. Mice were placed on an elevated wire mesh table. Testing was initiated with the 5.9 mN (0.6 g) von Frey filament (Stoelting Co, Wood Dale, IL, USA), using the up-down method to stimulate the mid-plantar surface of the hind paw until the mouse withdrew its paw. If no paw withdrawal was noted, the next higher weight filament was used. If paw withdrawal was observed, the next lower weight filament was used. The resulting pattern of 6 responses was tabulated and the 50% paw withdrawal threshold was calculated as described previously by us.
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The paw withdrawal frequency (PWF) to a standard von Frey monofilament with 9.8 mN (1.0 g) applied 10 times at an inter-stimulus interval of approximately 5 seconds to the plantar surface of the hind paw was also recorded.
Grip force to determine deep tissue/musculoskeletal pain. Peak forepaw grip force was measured using a computerized grip force meter (SA Maier Co., Milwaukee, WI) as previously described. Mice were held by the tail and allowed to grasp a wire-mesh grid with their forepaws. Grip force increases as mice are gradually pulled away from the mesh by the tail. The peak force exerted (up to 1 kg) was recorded and presented as the mean from three trials. Deep tissue hyperalgesia was defined as a decrease in grip force.
Withdrawal responses to heat stimuli. This was carried out using a Hargreaves apparatus. Radiant heat, from a heat source placed below, was delivered to the plantar surface of the hindpaw and paw withdrawal latency (PWL) was recorded in seconds. 48 Withdrawal responses to cold stimuli. Mice were placed on a cold plate at 4°C. PWL and PWF responses for each hind paw over a 2 minute period were recorded.
Balance and motor coordination. Mice were placed on a (0-72 rpm) accelerating rotarod apparatus (Model 7650, Ugo Basile, Verese, Italy). The latency to fall within a period of 5 minutes was recorded. Mice were subjected to 3 conditioning trials of 2 minutes, at intervals of 2 hours and required to remain on the bar for >60 seconds to be included in the experiment.
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Cutaneous Blood Flow
Cutaneous blood flow was measured non-invasively and in real time with a laser Doppler blood perfusion monitor (Laserflo R Model BPM 403, Vasamedics, Inc., St. Paul, Minnesota) as described previously. Hair on the dorsal skin over the thoracolumbar region was gently shaved with electric clippers one day before blood flow measurement.
The head of the Laserflo R probe (model PD-434, Vasamedics, St. Paul, MN) was placed on the shaved skin and blood flow values were obtained from the midpoint of the stable portion of the recordings, as described. 49 The built-in micro-processor calculates the blood flow in ml/min/100 g tissue as the product of velocity and volume values.
Cutaneous Mast Cell Staining
Sections approximately 6 microns thick were stained with Toluidine blue. Skin sections were dipped in a solution (pH 2.3) containing 0.025 g Toluidine blue O (Allied Chemical, Morristown, NJ), 2.5 ml 70% ethanol, and 47.5 ml of 1% sodium chloride solution at
